Papillary Renal Cell Carcinoma Sporadic

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-08-01
Clinical Trial Update: A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer [Phase 2]
A phase II trial evaluating the combination of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell …